Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Active, not recruiting · NCT02413736 · Registry updated 2025-03-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Active, not recruiting | Phase 3 | 2025-03-12 | NCT02413736 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Heikki Joensuu | 1 |
| Scandinavian Sarcoma Group | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Helsinki University Central Hospital | Helsinki | Finland | 10 |